Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by our Venture Partners, an elite group of world-renowned, serial scientist-entrepreneurs.
We focus on biomedical technology companies developing next-generation drugs, devices and diagnostics, and work closely with each portfolio company to build and grow the business from inception to exit.
The Catalio team comprises a unique combination of investment professionals and world-renowned, serial scientist-entrepreneurs. Together, we have a proven track record in starting up and spinning out category-defining businesses in the life sciences.
